Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 5/2024

17-03-2024 | Fertility | Gynecologic Endocrinology and Reproductive Medicine

Reproductive outcomes in women opting for fertility preservation after fertility-sparing surgery for borderline ovarian tumors

Authors: S. Cosyns, E. Van Moer, I. De Quick, H. Tournaye, M. De Vos

Published in: Archives of Gynecology and Obstetrics | Issue 5/2024

Login to get access

Abstract

Purpose

What are the reproductive outcomes of women who had fertility preservation (FP) using either oocyte or embryo vitrification after fertility-sparing surgery (FSS) for a borderline ovarian tumor (BOT)?

Methods

A retrospective, single-center cohort study was conducted between January 2013 and December 2021. Patients with BOT who resorted to FP by vitrifying oocytes or embryos were included. Both clinical and reproductive parameters were reviewed. The primary outcome was live birth.

Results

In total, thirteen patients who performed 31 FP cycles were included. Of those, six patients achieved eight live births after a mean follow-up period of 79 months. Three further pregnancies are still ongoing. All pregnancies/live births were obtained without using their cryopreserved oocytes or embryos.

Conclusion

Women who had FSS for BOT have favorable prospects of live offspring, even without the need to use their cryopreserved material. Fertility preservation in patients with BOT has to be considered as a tool to mitigate the risk of infertility that may arise in case of BOT recurrence requiring castrating surgery.
Literature
1.
2.
Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM et al (2004) Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35(8):910–917CrossRefPubMed
3.
Trope CG, Kaern J, Davidson B (2012) Borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 26(3):325–336CrossRefPubMed
4.
Skirnisdottir I, Garmo H, Wilander E, Holmberg L (2008) Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 123(8):1897–1901CrossRefPubMed
5.
Huang Y, Zhang W, Wang Y (2016) The feasibility of fertility-sparing surgery in treating advanced-stage borderline ovarian tumors: a meta-analysis. Taiwan J Obstet Gynecol 55(3):319–325CrossRefPubMed
6.
Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E (2012) Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 13(3):e103–e115CrossRefPubMed
7.
Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK et al (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48–52CrossRefPubMed
8.
Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29(6):707–723CrossRefPubMed
9.
Trope C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009) Diagnosis and treatment of borderline ovarian neoplasms “the state of the art.” Eur J Gynaecol Oncol 30(5):471–482PubMed
10.
Fauvet R, Demblocque E, Morice P, Querleu D, Darai E (2012) Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study. Ann Surg Oncol 19(3):941–947CrossRefPubMed
11.
Darai E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P (2013) Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 19(2):151–166CrossRefPubMed
12.
du Bois A, Trillsch F, Mahner S, Heitz F, Harter P (2016) Management of borderline ovarian tumors. Ann Oncol 27(Suppl 1):i20–i22CrossRefPubMed
13.
Camatte S, Morice P, Pautier P, Atallah D, Duvillard P, Castaigne D (2002) Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 109(4):376–380CrossRefPubMed
14.
Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G (1998) Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 82(1):141–146CrossRefPubMed
15.
Gouy S, Maria S, Faron M, Maulard A, Pautier P, Leary A et al (2021) Results after conservative surgery of stage ii/iii serous borderline ovarian tumors. Ann Surg Oncol 28(7):3597–3604CrossRefPubMed
16.
Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT (2000) Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 95(4):541–547PubMed
17.
Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E (2005) Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 83(2):284–290CrossRefPubMed
18.
De Munck N, Petrussa L, Verheyen G, Staessen C, Vandeskelde Y, Sterckx J et al (2015) Chromosomal meiotic segregation, embryonic developmental kinetics and DNA (hydroxy)methylation analysis consolidate the safety of human oocyte vitrification. Mol Hum Reprod 21(6):535–544CrossRefPubMed
19.
De Vos M, Smitz J, Thompson JG, Gilchrist RB (2016) The definition of IVM is clear-variations need defining. Hum Reprod 31(11):2411–2415CrossRefPubMed
20.
Delle Marchette M, Ceppi L, Andreano A, Bonazzi CM, Buda A, Grassi T et al (2019) Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery. Eur J Cancer 111:61–68CrossRefPubMed
21.
Plett H, Harter P, Ataseven B, Heitz F, Prader S, Schneider S et al (2020) Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol 157(2):411–417CrossRefPubMed
22.
Poulain M, Vandame J, Tran C, Koutchinsky S, Pirtea P, Ayoubi JM (2020) Fertility preservation in borderline ovarian tumor patients and survivors. Horm Mol Biol Clin Investig 43(2):179–186CrossRefPubMed
23.
Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V et al (2013) Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi160–vi170CrossRefPubMed
24.
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology (2013) Mature oocyte cryopreservation: a guideline. Fertil Steril 99(1):37–43CrossRef
25.
Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R et al (2008) Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online 17(2):265–267CrossRefPubMed
26.
Khiat S, Provansal M, Bottin P, Saias-Magnan J, Metzler-Guillemain C, Courbiere B (2020) Fertility preservation after fertility-sparing surgery in women with borderline ovarian tumours. Eur J Obstet Gynecol Reprod Biol 253:65–70CrossRefPubMed
27.
Prasath EB, Chan ML, Wong WH, Lim CJ, Tharmalingam MD, Hendricks M et al (2014) First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod 29(2):276–278CrossRefPubMed
28.
Segers I, Mateizel I, Van Moer E, Smitz J, Tournaye H, Verheyen G et al (2015) In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. J Assist Reprod Genet 32(8):1221–1231CrossRefPubMedPubMedCentral
29.
Filippi F, Martinelli F, Somigliana E, Franchi D, Raspagliesi F, Chiappa V (2020) Oocyte cryopreservation in two women with borderline ovarian tumor recurrence. J Assist Reprod Genet 37(5):1213–1216CrossRefPubMedPubMedCentral
30.
Huang JY, Buckett WM, Gilbert L, Tan SL, Chian RC (2007) Retrieval of immature oocytes followed by in vitro maturation and vitrification: a case report on a new strategy of fertility preservation in women with borderline ovarian malignancy. Gynecol Oncol 105(2):542–544CrossRefPubMed
31.
Segers I, Bardhi E, Mateizel I, Van Moer E, Schots R, Verheyen G et al (2020) Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Hum Reprod 35(9):2026–2036CrossRefPubMed
32.
Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, Loeffen EAH, Burns KC et al (2021) Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 22(2):e45–e56CrossRefPubMed
33.
Mangili G, Somigliana E, Giorgione V, Martinelli F, Filippi F, Petrella MC et al (2016) Fertility preservation in women with borderline ovarian tumours. Cancer Treat Rev 49:13–24CrossRefPubMed
34.
Masciangelo R, Bosisio C, Donnez J, Amorim CA, Dolmans MM (2018) Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum Reprod 33(2):212–219CrossRefPubMed
35.
36.
Falcone F, Breda E, Ferrandina G, Malzoni M, Perrone AM, Cormio G et al (2021) Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database. Gynecol Oncol 161(3):825–831CrossRefPubMed
37.
Jia SZ, Xiang Y, Yang JJ, Shi JH, Jia CW, Leng JH (2020) Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study. Hum Reprod 35(2):328–339CrossRefPubMed
38.
Helpman L, Yaniv A, Beiner ME, Aviel-Ronen S, Perri T, Ben-Baruch G et al (2017) Fertility preservation in women with borderline ovarian tumors - how does it impact disease outcome? A cohort study. Acta Obstet Gynecol Scand 96(11):1300–1306CrossRefPubMed
Metadata
Title
Reproductive outcomes in women opting for fertility preservation after fertility-sparing surgery for borderline ovarian tumors
Authors
S. Cosyns
E. Van Moer
I. De Quick
H. Tournaye
M. De Vos
Publication date
17-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 5/2024
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-024-07445-x

Other articles of this Issue 5/2024

Archives of Gynecology and Obstetrics 5/2024 Go to the issue

Maternal-Fetal Medicine

SPAM—sub partual analgesia with meptazinol: a prospective cohort study comparing intramuscular with intravenous administration

Gynecologic Endocrinology and Reproductive Medicine

Medical treatment for early pregnancy loss following in vitro fertilization compared to spontaneous pregnancies

General Gynecology

The use of LNG-IUS-19.5 mg in daily gynecological routine practice in Germany: data from the Kyleena™ Satisfaction Study (KYSS)

General Gynecology

Awareness, knowledge and attitudes of human papillomavirus infection, screening and vaccination: a survey study in Greece

Urogynecology

The effect of transobturator tape surgery on female sexual function: a systematic review and meta-analysis

Retraction Note

Retraction Note to: Fetal fibronectin (Quick Check fFN test) versus placental alpha microglobulin-1 (AmniSure test) for detection of premature rupture of fetal membranes